ChinaBio^® Partnering Forum 2012 Program Overview

2011 proved to be the most active year yet in China's short history of pharma partnering, with 60 licensing and co-development deals announced. In addition to the MNCs such as Bayer, Merck and Lilly, Chinese pharma like Hengrui and others are actively courting and securing cross-border partnerships. This panel assembles leading executives from these companies to discuss deals they've done and trends in cross-border partnering with China.

Moderator:
Greg B. Scott – President and Founder, ChinaBio^® LLC

Panelists:

• Jing-Shan "Jennifer" Hu, PhD – VP, Head of Innovation Center China, Global Drug Discovery, Bayer HealthCare Pharmaceuticals
• Jimmy Z. Zhang, PhD, MBA – Greater China Lead, Licensing, Acquisitions & External Research, Worldwide Licensing & Acquisitions, Merck & Co., Inc.
• Lianshan Zhang, PhD – President of Global R&D, Jiangsu Hengrui Medicine Co., Ltd.
• Tony Zhang, PhD – VP, Global External R&D, Asia, Eli Lilly and Company

ChinaBio^® Partnering Forum 2012

China is determined to become a major player in the global pharma market and is backing this intent with significant funding. Time will tell if this effort will result in an actual "homegrown" drug discovery/development platform and eventually in bringing novel molecules to the international markets. This panel features CEOs from four companies that intend to do just that. The panel will describe various business models and approaches to achieve China's endeavor to become a leader in novel drug development.

Moderator:
Karen Liu, PhD, EMBA – Partner, Kaiwu Capital

Panelists:

• Li Chen, PhD – CEO, Hua Medicine Ltd.
• Carl Firth, PhD, MBA – CEO and Founder, ASLAN Pharmaceuticals
• John Oyler, MBA – Founder and CEO, BeiGene
• Jinzi Wu, PhD – President & CEO, Ascletis, Inc.

ChinaBio^® Partnering Forum 2012

• Follow-on biologic legislation
• Patent reform
• Licensing considerations
• Federal funding and the Bayh-Dole Act

Speaker:

• Barbara R. Rudolph, PhD, JD – Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

ChinaBio^® Partnering Forum 2012

China's life science industry continues to grow, and significant deals between Western and Chinese entities are taking shape. Getting the deal done is a complex procedure that involves in-depth analyses of the status quo of both partners as well as the goals of the collaboration. The panel will take a behind-the-scenes look at the drivers, options and strategies it takes to form a successful partnership. Join dealmakers from these major players for a strategic look inside two important deals.

Moderators:
Ruediger Herrmann, PhD – Partner, WilmerHale
Alicia Hong – Head of China Practice, WilmerHale

Panelists:

• Jing-Shan "Jennifer" Hu, PhD – VP, Head of Innovation Center China, Global Drug Discovery, Bayer HealthCare Pharmaceuticals
• Lei Lv – Deputy Director, Overseas R&D Management Office, Tsinghua University
• May Wang, PhD – Senior VP, Strategic Alliance, Hutchison Medi Pharma
• Xiaolin Zhang, PhD – Vice President and Head of Innovation Center China, AstraZeneca

ChinaBio^® Partnering Forum 2012

China's pharma industry depends on venture capital to help bridge the gap between the bench and development. 2011 saw VC funding drop from the USD 1 billion+ invested in life science in 2010, but this was nearly made up for with USD 325 million invested by major companies in China and the West. VCs in China run the gamut from traditional firms to government-supported funds to corporate funds. Our panelists represent a variety of these firm types, all actively investing in the China pharma and biotech industry.

Moderator:
Greg B. Scott – President and Founder, ChinaBio^® LLC

Panelists:

• Peter Hua, PhD – Managing Partner, SB China Venture Capital
• Michael Keyoung, MD, PhD – Managing Director, Head of Burrill Pan-Asia, Burrill & Company
• Jimmy Wei, PhD – Venture Partner, KPCB China
• Jun Wu, PhD – Chairman and Managing Partner, Cenova Ventures

ChinaBio^® Partnering Forum 2012

This two-part session will first discuss some key drivers in successful life science deals in China, from "The Good" (things you need to take), to "The Bad" (things that hinder a deal), to "The Ugly" (things you need to leave at home). The second part of the session will take a closer look at assessing and valuing IP. The presentation will cover Western IP in China and how it is valued, to assessing the IP of a Chinese partner, what you are likely to see and what you should be looking for in your deal.

Speakers:

• Julian Thurston, JD – Partner, Morrison & Foerster LLP, UK
• Janet Xiao, PhD, JD – Partner, Morrison & Foerster LLP

ChinaBio^® Partnering Forum 2012

After years of chasing blockbuster opportunities in the US and established European markets, life science companies are shifting focus. The commercial strategies of large as well as mid-tier companies are discovering emerging markets. With its gigantic market opportunities, China is at the top of the list of new markets that are being targeted. Whether it is by building up a brick and mortar presence in China or by entering into commercialization deals with Chinese companies who already have a distribution/sales network in place, this panel will examine different strategies and deals companies are utilizing to penetrate the Chinese market.

Moderator:
Alfred W. Zaher, JD – Partner, Blank Rome

Panelists:

• Mark Mallon, MBA – Marketing Company President, China; Regional VP, Asia Pacific, AstraZeneca
• Martina Molsbergen – CEO, C14 Consulting Group
• James O'Mara – VP, Corporate Development, Ironwood Pharmaceuticals
• Jingbo Yan – Chief Scientific Advisor, Shanghai Pharmaceutical Industrial Co.

ChinaBio^® Partnering Forum 2012

The road to China can take many paths. Entrepreneurs and executives who make the commitment to come to a new land and chart a course toward success find that there are many hurdles, both professional and personal, as well as rewards in reaching their goals. Our Fireside Chat will again feature two industry leaders who have embarked on the adventure of China, sharing their stories—and dos and don'ts—of coming to China.

Siddhartha C. Kadia, PhD – President, Life Technologies Greater China
and
Mark Lotter, MBA – China CEO, SciClone / NovaMed Pharmaceuticals, Inc.

Interviewed by:
Eric Pierce – Publisher, BioCentury

ChinaBio^® Partnering Forum 2012

There is now general consensus that China is becoming a major center of global innovation. Big pharma is investing billions of dollars in major R&D centers in China. Over 3,200 novel molecules have been patented by Chinese companies and academic organizations over the last 10 years. But what is driving this increase in novel technology development?  What are the hotbeds of technology development?  What are the best universities and institutes for innovation? Chinese companies have traditionally been risk adverse, but with generic drug prices falling, are their R&D budgets increasing to stimulate innovation and profits? And what are local governments and life science parks doing to encourage innovation? Here are the answers to these and other questions from executives, academics and officials who are actively driving innovation in China.

Moderator:
Don Qiu, PhD, MBA – General Manager, ChinaBio^® LLC

Panelists:

• Tomas Landh, PhD – Director, Strategy and Sourcing, Diabetes Research Unit, Novo Nordisk
• Yuwen Liu, MBA – Chairwoman & CEO, BioBay
• Stella Xu, PhD – Regional Head, Greater China and Southeast Asia, Roche Partnering
• Yizhun Zhu, MD, PhD – Dean, School of Pharmacy, Fudan University

ChinaBio^® Partnering Forum 2012